| Size | Price | |
|---|---|---|
| 1mg | ||
| Other Sizes |
| Targets |
Ursodeoxycholic acid-d5 targets the same receptors as its non-deuterated parent compound: the farnesoid X receptor (FXR), a nuclear receptor that regulates bile acid synthesis, lipid metabolism, and glucose homeostasis; and the G-protein-coupled bile acid receptor 5 (TGR5), which is involved in energy metabolism and inflammation. The deuterium labeling does not alter receptor binding specificity.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
As a stable isotope-labeled compound, ursodeoxycholic acid-d5 is not used for activity studies. The non-deuterated UDCA has been extensively studied in vitro. It regulates the expression of genes involved in bile acid synthesis, transport, and detoxification. UDCA has cytoprotective effects, reducing apoptosis in hepatocytes and cholangiocytes. It also has anti-inflammatory and antioxidant properties. In vitro, UDCA inhibits the production of inflammatory cytokines and protects against cell death induced by bile acids. The deuterated version is used as an internal standard for quantification of UDCA in these studies. |
| ln Vivo |
In vivo, ursodeoxycholic acid (non-deuterated) is an orally active therapeutic used for the treatment of primary biliary cholangitis (PBC), gallstones (cholelithiasis), and other cholestatic liver diseases. It reduces bile acid toxicity, improves liver function tests, and slows disease progression. UDCA is also being investigated for its potential benefits in non-alcoholic fatty liver disease (NAFLD) and other gastrointestinal disorders. The deuterated version (d5) is not used for in vivo efficacy studies but can be administered as a tracer for pharmacokinetic studies.
|
| Enzyme Assay |
For non-cellular assays (analytical quantification), ursodeoxycholic acid-d5 is prepared as a stock solution in methanol (1 mg/mL). For LC-MS/MS analysis, a calibration curve for UDCA is prepared in human serum or plasma (0.1-1000 ng/mL) with a fixed concentration of UDCA-d5 (e.g., 50 ng/mL). Sample preparation: 500 uL plasma + 25 uL internal standard + 1 mL acetonitrile for protein precipitation. After centrifugation, the supernatant is evaporated to dryness, reconstituted in 100 uL mobile phase (methanol:water:formic acid), and injected onto a C18 column (2.1×50 mm, 1.8 um).
|
| Cell Assay |
For cell-based assays, primary human hepatocytes or liver cell lines (e.g., HepG2, Huh7) are seeded in 6-well plates (1×10⁶ cells/well) in DMEM with 10% FBS. After 24 hours, cells are treated with UDCA (0.1-100 uM) or UDCA-d5 (as an internal standard for quantification) for 24-48 hours. Gene expression of FXR target genes (e.g., SHP, BSEP, CYP7A1) is measured by qPCR. Apoptosis is assessed by caspase-3/7 activity (luminescence assay). Inflammatory cytokines (IL-6, TNF-alpha) in culture medium are measured by ELISA.
|
| Animal Protocol |
For in vivo animal experiments, UDCA is administered to rodents for various indications. For cholestasis models, mice are fed a cholic acid-supplemented diet or undergo bile duct ligation (BDL). UDCA is administered orally at doses of 25-100 mg/kg/day for 7-14 days. Serum liver enzymes (ALT, AST, ALP), bilirubin, and bile acids are measured. Liver tissue is collected for histology (H&E staining, Sirius Red for fibrosis) and gene expression analysis. For pharmacokinetic studies, UDCA-d5 can be administered to rats or mice as a tracer to study UDCA absorption, distribution, metabolism, and excretion.
|
| ADME/Pharmacokinetics |
Ursodeoxycholic acid-d5 has a molecular formula of C24H3₅D₅O4 and a molecular weight of approximately 397.60. The compound is soluble in DMSO, methanol, and ethanol. It should be stored as a powder at -20degC, protected from light and moisture. The deuterium labels are stable and do not exchange under physiological conditions. UDCA-d5 is chemically identical to UDCA except for the substitution of five hydrogen atoms with deuterium.
|
| Toxicity/Toxicokinetics |
Ursodeoxycholic acid-d5 is a stable isotope-labeled compound with low toxicity at analytical concentrations. The non-deuterated parent compound, UDCA, has been extensively used in humans for decades with a well-established safety profile. Common side effects include mild diarrhea, nausea, and abdominal discomfort. UDCA is generally well-tolerated at therapeutic doses (10-20 mg/kg/day). For use as an internal standard, no toxicity is expected due to trace amounts. Standard laboratory safety precautions for handling bile acids should be followed.
|
| References | |
| Additional Infomation |
Ursodeoxycholic acid-d5 is an analytical standard and research tool. The non-deuterated parent compound, ursodeoxycholic acid (Ursodiol), is an FDA-approved drug used for the treatment of primary biliary cholangitis (PBC) and for dissolving radiolucent gallstones. It is available by prescription. UDCA-d5 is used exclusively as an internal standard for quantitative LC-MS/MS analysis in clinical and research settings. It is not intended for human therapeutic use. Clinical trials with UDCA have been conducted for various indications (PBC, NAFLD, NASH, and gallstones). The deuterated version is not used in these trials.
|
| Molecular Formula |
C24H40O4
|
|---|---|
| Molecular Weight |
392.572008132935
|
| Exact Mass |
397.324
|
| CAS # |
93701-18-9
|
| PubChem CID |
45040670
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
605
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
[2H][C@]1(C(C[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@H](C[C@@H]2C1([2H])[2H])O)CC[C@@H]4[C@H](C)CCC(=O)O)C)C)([2H])[2H])O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5473 mL | 12.7366 mL | 25.4732 mL | |
| 5 mM | 0.5095 mL | 2.5473 mL | 5.0946 mL | |
| 10 mM | 0.2547 mL | 1.2737 mL | 2.5473 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
